{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"CLSNATLUIXZPMV-UHFFFAOYSA-N","prefName":"JJKK 048","symbol":"JJKK 048","iupacName":"[4-[bis(1,3-benzodioxol-5-yl)methyl]piperidin-1-yl]-(1,2,4-triazol-1-yl)methanone","aliases":["GTPL9481","EX-A14193","DA-74648"],"cas":null,"pubchemCid":"76313567","chebiId":null,"smiles":"C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)C4=CC5=C(C=C4)OCO5)C(=O)N6C=NC=N6","molecularFormula":"C23H22N4O5","molecularWeight":434.4,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/76313567"}},"classification":{"family":"ecs_tool","familyLabel":"ECS modulator (research)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (research tool)","summaryFr":"No biosynthetic pathway: a chemically synthesised molecule belonging to the class of piperidine triazole ureas.","originNote":"Fully synthetic molecule, part of a series of piperazine and piperidine triazole ureas developed at the University of Eastern Finland in Kuopio. No natural occurrence is known: it is a laboratory compound.","discovered":""},"pharmacology":{"summaryFr":"JJKK 048 is a synthetic triazole urea that inhibits monoacylglycerol lipase (MAGL), the enzyme responsible for ending the action of 2-arachidonoylglycerol (2-AG). First described in 2013 by a team at the University of Eastern Finland in Kuopio, it inhibits human MAGL with an IC50 below 0.4 nM (Aaltonen et al., 2013). ChEMBL data from 2014 give an IC50 above 4 000 nM on human FAAH (Korhonen et al., 2014). In laboratory animals, the 2016 study reports a massive rise in brain 2-AG without change in anandamide, and analgesia in the writhing test at a low dose, without cannabimimetic effects (Aaltonen et al., 2016). The abstracts consulted report no affinity constant at CB1 or CB2, and no pharmacokinetic or clinical data in humans.","receptorSummaryFr":"Inhibitor of monoacylglycerol lipase (MAGL), the enzyme that ends the action of 2-arachidonoylglycerol (2-AG). The IC50, the concentration that halves enzyme activity, is below 0.4 nM on human MAGL as on rodent MAGL (Aaltonen et al., 2013). The authors report low cross-reactivity with other targets of the endocannabinoid system and high specificity among metabolic serine hydrolases, measured by activity-based profiling on mouse brain and on human melanoma cells. On human FAAH, the IC50 exceeds 4 000 nM in ChEMBL data (Korhonen et al., 2014). The abstracts consulted report no affinity constant for CB1 or CB2.","binding":[{"target":"MAGL (monoacylglycérol lipase)","efficacy":"modulator","relativeActivity":95,"reported":"IC50 inférieure à 0,4 nM sur la MAGL humaine (Aaltonen et coll., 2013) ; IC50 de 0,363 nM dans les données ChEMBL de 2014 (Korhonen et coll., 2014)","confidence":"medium"},{"target":"FAAH","efficacy":"modulator","relativeActivity":15,"reported":"IC50 supérieure à 4 000 nM sur la FAAH humaine (Korhonen et coll., 2014, données ChEMBL)","confidence":"medium"}],"references":[{"label":"Aaltonen et coll., Urées de triazole pipéraziniques et pipéridiniques, inhibiteurs ultrapuissants et très sélectifs de la MAGL, Chem Biol, 2013","pmid":"23521796","doi":"10.1016/j.chembiol.2013.01.012","url":"https://pubmed.ncbi.nlm.nih.gov/23521796/"},{"label":"Aaltonen et coll., Caractérisation in vivo du JJKK 048, inhibiteur ultrapuissant de la MAGL, J Pharmacol Exp Ther, 2016","pmid":"27451409","doi":"10.1124/jpet.116.233114","url":"https://pubmed.ncbi.nlm.nih.gov/27451409/"},{"label":"Korhonen et coll., Carbamates et carboxamides de pipérazine et de pipéridine comme inhibiteurs de la FAAH et de la MAGL, Bioorg Med Chem, 2014","pmid":"25282655","doi":"10.1016/j.bmc.2014.09.012","url":"https://pubmed.ncbi.nlm.nih.gov/25282655/"},{"label":"ChEMBL, fiche composé CHEMBL3087181 (activités MAGL et FAAH du JJKK 048)","pmid":null,"doi":null,"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3087181/"},{"label":"PubChem, notice du composé JJKK 048 (CID 76313567)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/76313567"},{"label":"ANSM, liste consolidée des stupéfiants (mise à jour du 16 février 2026)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":6},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":2},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":3},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":2},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":2}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised European Union control measure is known to target this molecule, according to the sources consulted; control, where it exists, falls to national legislation. It is also absent from the INCB Green List 2026, which lists the substances subject to the 1971 Convention.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"JJKK 048 is not named in any annex of the decree of 22 February 1990 fixing the list of narcotics, as consolidated by the ANSM on 16 February 2026. It is not a tetrahydrocannabinol, nor an ester, ether or salt of one: the generic clause covering them therefore does not capture it. Its structure, a piperidine triazole urea with no indole, indazole, naphthyl, cyclohexylphenol, thiazole or pyrrolopyridine core, meets none of the generic family definitions in that list. It is therefore unscheduled in France. This absence of classification does not amount to an authorisation: the sources consulted describe no use outside research, and a later classification by ministerial order remains possible.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Aaltonen et coll., Urées de triazole pipéraziniques et pipéridiniques, inhibiteurs ultrapuissants et très sélectifs de la MAGL, Chem Biol, 2013","pmid":"23521796","doi":"10.1016/j.chembiol.2013.01.012","url":"https://pubmed.ncbi.nlm.nih.gov/23521796/"},{"label":"Aaltonen et coll., Caractérisation in vivo du JJKK 048, inhibiteur ultrapuissant de la MAGL, J Pharmacol Exp Ther, 2016","pmid":"27451409","doi":"10.1124/jpet.116.233114","url":"https://pubmed.ncbi.nlm.nih.gov/27451409/"},{"label":"Korhonen et coll., Carbamates et carboxamides de pipérazine et de pipéridine comme inhibiteurs de la FAAH et de la MAGL, Bioorg Med Chem, 2014","pmid":"25282655","doi":"10.1016/j.bmc.2014.09.012","url":"https://pubmed.ncbi.nlm.nih.gov/25282655/"},{"label":"ChEMBL, fiche composé CHEMBL3087181 (activités MAGL et FAAH du JJKK 048)","pmid":null,"doi":null,"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3087181/"},{"label":"PubChem, notice du composé JJKK 048 (CID 76313567)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/76313567"},{"label":"ANSM, liste consolidée des stupéfiants (mise à jour du 16 février 2026)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}],"meta":{"slug":"jjkk-048","url":"https://en.phytogrammes.com/wiki/jjkk-048","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}